Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Ultimately, is Eli Lilly still a buy despite these detrimental ... charge equal to $1.72 per share due to its acquisition of Scorpion Therapeutics. This caused Lilly to reduce its full-year ...

Eli Lilly on Thursday reported first-quarter ... related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of ...

The new threat has Eli Lilly investors running scared, but Wall Street analysts insist Eli Lilly stock is still a buy. Positive jobs news and positive rumors out of China are lifting stock markets ...

Eli Lilly and Creyon Bio have entered into a partnership worth ... Lilly also announced in January that it would be expanding its oncology pipeline by acquiring Scorpion Therapeutics’ PI3Kα inhibitor ...

Lilly turned in strong first-quarter results ... the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to treat breast cancer.